BackgroundCheck.run
Search For

Zachary D Prensky, 512373 Broadway APT 1033, New York, NY 10024

Known as:
Zachary David Prensky Eileen Prensky Zachery Preust Zachary Y Zachery Y
Related to:
Donald J Donofrio 50

Zachary Prensky Phones & Addresses

2373 Broadway APT 1033, New York, NY 10024    212-7990287   

372 Central Park W, New York, NY 10025    212-2801070    212-2802449    212-2804033   

382 Central Park W, New York, NY 10025    212-2804033   

372 Central Park W APT 9S, New York, NY 10025   

Spring Valley, NY   

Lakewood, NJ   

Brooklyn, NY   

Fair Lawn, NJ   

372 Central Park W APT 9S, New York, NY 10025    212-2802449   

Work

Position: Executive, Administrative, and Managerial Occupations

Education

Degree: Associate degree or higher
Get Report
Control this profile

Mentions for Zachary D Prensky

Zachary Prensky resumes & CV records

Resumes

Zachary Prensky Photo 4

Grand 'Poo-Bah' At Little Bear Investments

Position:
Managing Director at Little Bear Investments
Location:
Greater New York City Area
Industry:
Banking
Work:
Little Bear Investments since 1997
Managing Director
Education:
MTA
Yeshiva University
Skills:
Financial Analysis, Mergers, Investments
Zachary Prensky Photo 5

Manager At Little Bear Investments Llc

Location:
Greater New York City Area
Industry:
Investment Banking

Publications & IP owners

Us Patents

Psychotropic Agents And Uses Thereof

US Patent:
2020007, Mar 12, 2020
Filed:
Apr 15, 2019
Appl. No.:
16/383933
Inventors:
- New York NY, US
Vincent T. Grattan - New York NY, US
Zachary Prensky - New York NY, US
International Classification:
C07D 207/09
A61K 31/40
A61K 45/06
A61K 31/166
A61P 25/18
C07C 317/36
Abstract:
Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or a2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of dopamine and/or serotonin in the brain, either individually or in combination with other CNS active agents.

Psychotropic Agents And Uses Thereof

US Patent:
2020005, Feb 20, 2020
Filed:
Sep 5, 2019
Appl. No.:
16/561829
Inventors:
- New York NY, US
Vincent T. GRATTAN - New York NY, US
Zachary PRENSKY - New York NY, US
International Classification:
C07D 207/09
A61K 31/40
A61K 45/06
A61K 31/166
A61P 25/18
C07C 317/36
Abstract:
Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of dopamine and/or serotonin in the brain, either individually or in combination with other CNS active agents.

Psychotropic Agents And Uses Thereof

US Patent:
2020000, Jan 2, 2020
Filed:
Sep 5, 2019
Appl. No.:
16/561767
Inventors:
- New York NY, US
Vincent T. Grattan - New York NY, US
Zachary Prensky - New York NY, US
International Classification:
C07D 207/09
C07C 317/36
A61P 25/18
A61K 31/166
A61K 45/06
A61K 31/40
Abstract:
Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of dopamine and/or serotonin in the brain, either individually or in combination with other CNS active agents.

Psychotropic Agents And Uses Thereof

US Patent:
2018017, Jun 21, 2018
Filed:
Feb 14, 2018
Appl. No.:
15/896851
Inventors:
- New York NY, US
Vincent T. GRATTAN - New York NY, US
Zachary PRENSKY - New York NY, US
International Classification:
C07D 207/09
A61K 31/40
A61K 45/06
A61P 25/18
C07C 317/36
A61K 31/166
Abstract:
Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of dopamine and/or serotonin in the brain, either individually or in combination with other CNS active agents.

Psychotropic Agents And Uses Thereof

US Patent:
2018015, Jun 7, 2018
Filed:
Nov 28, 2017
Appl. No.:
15/824966
Inventors:
- New York NY, US
Vincent T. GRATTAN - New York NY, US
Zachary PRENSKY - New York NY, US
International Classification:
C07D 207/09
C07C 317/36
A61K 31/40
A61K 31/166
A61K 45/06
A61P 25/18
Abstract:
Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of dopamine and/or serotonin in the brain, either individually or in combination with other CNS active agents.

Possible Relatives

David N Prensky  Zachary S Johnson  Zachary K Johnston  Zachary Stanford  Zachary L White  Zachary C Jolly  Zachary M Jones  Zachary Stanley  Zachary M Stanton  Zachary B Steele 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.